Arcus Biosciences presented promising results for its kidney cancer treatment on Tuesday, which competitors Merck have also been developing. Following this announcement, the shares of Arcus Biosciences experienced a significant increase, rebounding from a premarket decline. This sudden surge in share value was driven by the positive reception of the Merck-rivaling cancer treatment reveal.
